Methylation profiling in the contemporary management of meningioma
Journal of Neuro-Oncology · 2024
DOI: 10.1007/s11060-024-04825-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Alexander P Landry und 4 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, MacFeeters Hamilton Neuro-Oncology Program, University Health Network and University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Meningioma, DNA Methylation, Meningeal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: The last decade has seen major international research efforts focus on better understanding disease heterogeneity in meningioma. Multiple molecular platforms have generated significant biological and clinical utility, and there is a need to translate these findings into routine clinical practice. Here we review the role of DNA methylation profiling in meningioma and advocate for its widespread adoption. METHODS: We review modern DNA methylation-based classification and outcome prediction tools in meningioma. Biological classifiers, which were constructed agnostic to outcome using unsupervised approaches, outcome predictors, and liquid biopsy models are discussed in detail. RESULTS: DNA methylation has been used for biological classification and outcome in meningioma with considerable success. Several groups have proposed novel molecular classification systems which share similar features with one another and outperform WHO grade in their ability to predict outcome and explain subgroup-specific biological processes. In addition, recent studies have suggested a role for methylation-based liquid-biopsy in meningioma, which represents an exciting avenue for further exploration. CONCLUSIONS: DNA methylation profiling has been revolutionary in meningioma. There is a need for widespread adoption of these approaches to personalize care and inform clinical trial design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Margaret Cancer Centre, MacFeeters Hamilton Neuro-Oncology Program, University Health Network and University of Toronto, Toronto, ON, Canada.
- Division of Neurosurgery, Department of Surgery, University of Toronto, 399 Bathurst Street, West Wing 4-427, Toronto, ON, M5T 2S8, Canada.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
- Princess Margaret Cancer Centre, MacFeeters Hamilton Neuro-Oncology Program, University Health Network and University of Toronto, Toronto, ON, Canada. gelareh.zadeh@uhn.ca.
- Division of Neurosurgery, Department of Surgery, University of Toronto, 399 Bathurst Street, West Wing 4-427, Toronto, ON, M5T 2S8, Canada. gelareh.zadeh@uhn.ca.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. gelareh.zadeh@uhn.ca.
Förderung
- NCI NIH HHS
Zitieren
APA
Landry, A. P., Yefet, L. S., Wang, J. Z., Zadeh, G., & Nassiri, F. (2024). Methylation profiling in the contemporary management of meningioma. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04825-w
Vancouver
Landry AP, Yefet LS, Wang JZ, Zadeh G, Nassiri F. Methylation profiling in the contemporary management of meningioma. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04825-w
BibTeX
@article{Landry2024,
author = {Landry, Alexander P and Yefet, Leeor S and Wang, Justin Z and Zadeh, Gelareh and Nassiri, Farshad},
title = {Methylation profiling in the contemporary management of meningioma},
journal = {Journal of Neuro-Oncology},
year = {2024},
doi = {10.1007/s11060-024-04825-w}
}
EUVIMED